# A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

> **NCT06138327** · PHASE1 · WITHDRAWN · sponsor: **BioMarin Pharmaceutical**

## Conditions studied

- Hyperoxaluria
- Nonalcoholic Fatty Liver Disease
- Kidney Stone

## Interventions

- **DRUG:** BMN 255
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06138327
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-26
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138327, "A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06138327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*